POSTER SESSION II Monday, March 24, 2003   —  1:00 - 4:30 PM Exhibit Hall A - C GENITOURINARY PATHOLOGY 68 Micropapillary Variant of Urothelial Carcinoma of the Urinary Bladder: A Clinicopathological and Immunohistochemical Study (767) H Samaratunga, K Khoo Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia 69 Expression of Maspin Protein in Primary Urothelial Carcinoma (752) X Pang, I Sesterhenn, CJ Davis, Z Zhou, F Mostofi Armed Forces Institute of Pathology, Washington, DC; Center for Prostate Disease Research, USUHS, Rockville, MD 70 TIMP-2 as a Multifunctional Molecule Whose Expression Is Associated with Adverse Prognosis of Patients with Urothelial Bladder Carcinomas (744) LL Nakopoulou, HH Gakiopoulou, A Siatelis, NP Givalos, EG Panayotopoulou, I Tsirmpa, C Stravodimos, A Giannopoulos Medical School, the National and Kapodistrian University of Athens; Medical School, University of Athens, Athens, Greece 71 Clinicopathologic Features, Cell Cycle Regulators and Differentiation Markers as Prognostic Factors in Recurrence, Progression and Survival of Stage T1 Grade 3 Bladder Cancer (731) A Lopez-Beltran, RJ Luque, J Alvarez, F Merlo, A Quintero, MJ Requena Cordoba University Medical School and Reina Sofia University Hospital, Cordoba, Spain; Jaen University Hospital, Jaen, Spain 72 Micropapillary Transitional Cell Carcinoma of the Urinary Bladder. A Study of 8 Cases (730) JI Lopez, L Andres, L Etxegarai, C Ereno, FJ Bilbao Hospital de Basurto, UPV/EHU, Bilbao, Bizkaia, Spain 73 A Molecular and Immunohistochemical Study of Cell Cycle Regulators in Urothelial Bladder Neoplasms (UCN) (728) A Llombart-Bosch, D Ramos, JA Lopez-Guerrero, J Rubio, A Pellin, I Iborra, E Solsona-Narbon Medical School, University of Valencia, Spain; Service of Urology IVO, Valencia, Spain 74 Detection of p16, p53, p21 and RB Expression in a Tissue Microarray of Bladder Urothelial Carcinoma. A Comparison of Immunohistochemistry and Laser Scanning Cytometry (687) R Gandour-Edwards, A Garcia-Williams, R Reynoso, M Gallagher, P Lara, J LaSalle, R deVere White University of California Davis, Sacramento, CA 75 Non-Endothelial KDR/flk-1 Expression Is Associated with Increased Survival of Patients with Urothelial Bladder Cancer (686) HH Gakiopoulou, EG Panayotopoulou, JX Mavrommatis, A Konstantinidou, A Giannopoulos, LL Nakopoulou The National and Kapodistrian University of Athens, Athens, Greece; Laikon Hospital, University of Athens, Athens, Greece 76 Urothelial Carcinoma of the Renal Pelvis (747) S Olgac, G Dalbagni, VE Reuter Memorial Sloan Kettering Cancer Center, New York City, NY 77 Nephrogenic Adenoma (NA): An Immunohistochemical (ICH) Study of 40 Cases (748) E Oliva, H Moch, R Cabrera, RH Young, V Reuter, MB Amin Massachusetts General Hospital, Boston, MA; University of Basel, Basel, Switzerland; Sloan Kettering Cancer Center, New York, NY; Emory Hospital, Atlanta, GA 78 Human Neutrophilic Defensin (1/2/3) [HND (1/2/3)] Immunohistochemical (IHC) Staining in Urinary Bladder Cancer: Validation of a Novel Tumor Marker Discovered by Urine Proteomic Profiling (738) SE Mendrinos, MB Amin, SD Lim, JDL Nolen, C Cohen Emory University School of Medicine, Atlanta, GA 79 Comparison of Clinical Outcomes of Conventional High Grade Invasive Urothelial Carcinoma with Urothelial Carcinoma Exhibiting Aggressive Histological Features (806) H Zhang, F Bianco, T Bismar, G Bentley, W Sakr, D Grignon, M Che Harper University Hospital and Karmanos Cancer Institute, Wayne State University, Detroit, MI 80 Multiplex-MSP as a Potential Ancillary Tool in Urothelial Surgical Pathology and Cytopathology (755) RT Pu, LE Laitala, DP Clark Johns Hopkins Medical Institutions, Baltimore, MD 81 Cell Cycle Related Proteins Expression in Bladder Cancer : Validation and Analysis with Tissue Array (722) E Latulippe, J Rigaud, H Hovington, A Lessard, H Larue, L Lacombe, Y Fradet Hotel Dieu de Quebec, Quebec, QC, Canada 82 Expression of Caveolin-1 and -2 in Urothelial Carcinoma of the Urinary Bladder Correlates with Tumor Grade and Squamous Differentiation (678) A Fong, E Garcia, L Gwynn, MJ Fazzari, M Li Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY 83 Gene Expression Profile in Progression of Bladder Cancer Revealed by cDNA Microarray Analysis (715) JH Kim, T Tuziak, Z Whang, DL Gold, L Hu, K Baggerly, W Zhang, B Czerniak The University of Texas, MD Anderson Cancer Center, Houston, TX 84 ALK Expression in Reactive Pseudosarcomatous Myofibroblastic Proliferations of the Genitourinary Tract (697) MS Hirsch, P Dal Cin, CDM Fletcher Brigham and Women's Hospital & Harvard Medical School, Boston, MA 85 Expression of Uroplakins in Nephrogenic Adenoma: Immunohistochemical Evidence Supporting Urothelial Origin (787) GX Tong, J Melamed, P Levine, DA Popiolek, TT Sun New York University Medical Center, New York, NY 86 ALK1 Expression in Pseudosarcomatous Myofibroblastic Tumor (PSFMT) of the Urinary Bladder (795) T Tsuzuki, C Magi-Galluzzi, JI Epstein The Johns Hopkins Hospital, Baltimore, MD 87 Incipient Phases of Human Bladder Neoplasia Identified by Whole-Organ Mapping of Allelic Losses on Chromosome 13 (716) M-S Kim, J Jeong, D-S Yoon, R-D Zhang, L Li, JZ Li, K Ptaszynski, K Tang, HB Grossman, WF Benedict, S Scherer, DA Johnston, B Czerniak The University of Texas M D Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX 88 Expression of Skp2 and p27 in Transitional Cell Carcinoma of Urinary Bladder (778) JW Shim, JS Cho, HR Park, HS Shin Hallym University, Korea 89 Postoperative Bladder Washing Cytology after Transurethral Resection Predicts Recurrence of Urothelial Carcinoma (699) KA Iczkowski, G Katz, CJ Cascione, DD Grier Urology, University of Florida College of Medicine and VA Medical Center, Gainesville, FL 90 Urothelial Carcinoma of the Upper Urinary Tract: Inverted Growth Pattern Is Predictive of Microsatellite Instability (647) H Blaszyk, A Hartmann, LJ Burgart, JC Cheville UVM, Burlington, VT; University of Regensburg, Regensburg, Germany; Mayo Clinic, Rochester, MN 91 Volume-Related Patterns of Tumor Distribution of Prostate Carcinoma (788) G Torlakovic, E Torlakovic, JM Nesland, A Reith, HE Danielsen The Norwegian Radium Hospital, Oslo, Norway 92 Discovery of New Markers of Prostate Cancer (PCA) among the Genes under Negative Control of Tumor Supressors (TSG) Using a Combination of Gene Expression Profiling (EP) and Chromogenic In Situ RNA Hybridization (CISH) on Tissue Microarrays (TMA) (785) JE Tash, DG Hicks, RR Tubbs, M Skacel, JD Pettay, K Gurova, V Krivovrysenko, E Feinstein, JA Brainard, A Gudkov Lerner Research Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH 93 Cyclin D1 as a Predictor of Biochemical Recurrence in Prostate Carcinoma. Analysis by Tissue Microarrays (768) A Santos-Briz, E Munoz, P Antunez, T Flores, J Silva, A Rodriguez, G Usera, L Sanchez, A Diez, A Bullon, FJ Martinez-Tello Universidad Salamanca; Hospital Universitario, Salamanca; Hospital 12 de Octubre, Madrid; Centro Nacional de Investigaciones Oncologicas, Madrid, Spain 94 Impact of Extended Biopsy Schemes on Prostatic Adenocarcinoma (PAC) Detection in Repeat Biopsy Specimens (745) T Nazeer, S Anwar, TA Jennings, JS Ross, B Mian Albany Medical College, Albany, NY 95 Expression of EphA2 Kinase in Prostatic Cancers and Benign Prostatic Tissues by Immunohistochemical Studies (736) S Mehra, M Chung-Park, B-R Wei, B Wang MetroHealth Medical Center, Cleveland, OH 96 Topographic Distribution and Histopathological Features of Small Foci of Grade 1 and 2 Prostatic Adenocarcinoma (733) KT Mai, EC Belanger University of Ottawa, Ottawa, ON, Canada 97 Aberrant CpG Island Methylation of Multiple Genes in Prostate Cancer and Premalignant Lesions (710) GH Kang, S Lee Seoul National University College of Medicine, Seoul, Korea; National Cancer Center, Ilsan, Korea 98 P504S Antibody Expression in Putative Precursor Lesions of Prostate Carcinoma (PCa)- High Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Adenomatous Hyperplasia (AAH) (691) N Gupta, M de Peralta-Venturina, A Gown, R Beach, P Salles, H Yaziji, MB Amin Henry Ford Hospital, Detroit, MI; Phenopath Laboratories and IRIS, Seattle, WA; Emory University Hospital, Atlanta, GA 99 Down Regulation of FHIT Expression in Prostatic Carcinoma (679) RL Fouts, GE Sandusky, S Zhang, GJ Eckert, MO Koch, TM Ulbright, JN Eble, L Cheng Indiana University School of Medicine, Indianapolis, IN; Lilly Research Laboratories, Indianapolis, IN 100 Identification of c-erbB-2 Protein Expression in Prostate Carcinoma (671) S Erdogan, S Zorludemir, B Soyupak, Zu Tansug Cukurova University, Medical Faculty, Adana, Turkey 101 Quantitative GSTP1 Methylation Improves the Detection of Prostate Adenocarcinoma in Sextant Biopsies (670) JI Epstein, SV Harden, H Sanderson, SN Goodman, D Sidransky The Johns Hopkins Hospital, Baltimore, MD 102 Angiogenesis in HGPIN: Expression of VEGF, FLK/KDR and Microvessel Density in HGPIN and Its Relationship to Prostate Cancer (667) I de Torres, J Pallares, F Rojo, J Iriarte, J Morote Vall de Hebron Hospitals, Autonomous University of Barcelona, Barcelona, Catalunya, Spain 103 Mucin-Producing Urothelial-Type Adenocarcinoma of Prostate: A Diagnostic Challenge Addressed by Immunohistochemistry (663) MW Curtis, AJ Evans, JR Srigley University Health Network, Toronto, ON, Canada; Credit Valley Hospital, Mississauga, ON, Canada 104 Intraprostatic Fat: Does It Exist? (642) A Billis , School of Medicine (UNICAMP), Campinas, SP, Brazil 105 Prostate Cancer with Bladder Neck Involvement: Pathologic Findings and Recurrence-Free Survival after Radical Prostatectomy (643) A Billis, LLL Freitas, LA Magna, AB Samara, U Ferreira Medical Genetics and Statistics; Urology, School of Medicine (UNICAMP), Campinas, SP, Brazil 106 DAX-1 Expression Is Associated with Decreased Recurrence-Free Survival in Lymph Node Negative Low-Grade Prostate Carcinoma (632) M Amrikachi, R Li, N Weigel, TM Wheeler, A Frolov, G Ayala Baylor College of Medicine and the Methodist Hospital, Houston, TX 107 All That Is Micropapillary Is Not High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN): Circumferential Micropapillary Perineural Invasion (CMPNI) - A Potential Pitfall in the Recognition of Invasive Prostatic Adenocarcinoma (631) MB Amin, RA Cabrera, SD Lim, M Varma Emory University School of Medicine, Atlanta, GA; University Hospital of Wales, Cardiff, Wales, United Kingdom 108 Use of a Novel Immunohistochemical (IHC) Panel (P504S, p63 and 34[Beta]E12) in the Diagnosis of Post-Radiation Therapy (PRT) Prostate Cancer (PCa) (630) M Amin, R Beach, AM Gown, H Yaziji, R Malhotra, MB Amin William Beaumont Hospital, Royal Oak, MI; Emory University School of Medicine, Atlanta, GA; PhenoPath Laboratories and IRIS, Seattle, WA 109 Possible Determination of Transition Zone (TZ) vs. Peripheral Zone (PZ) Origin of Stage T1c Prostate Carcinoma (Pca) by Histological Features on Preoperative Biopsy (666) DS Dave, MP Revelo, R Roberts, GS Jack, JA Smith, Jr, SS Chang, MS Cookson, SB Shappell Vanderbilt University Medical Center, Nashville, TN